These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25227799)

  • 1. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
    Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A
    Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HSP90 Gene Expression with 17-DMAG Nanoparticles in Breast Cancer Cells.
    Mellatyar H; Talaei S; Nejati-Koshki K; Akbarzadeh A
    Asian Pac J Cancer Prev; 2016; 17(5):2453-7. PubMed ID: 27268613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
    Nam S; Kim H; Hong D; Park JB; Kim SJ
    Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of inhibitory effect of 17-DMAG nanoparticles and free 17-DMAG in HSP90 gene expression in lung cancer.
    Mellatyar H; Akbarzadeh A; Rahmati M; Ghalhar MG; Etemadi A; Nejati-Koshki K; Zarghami N; Barkhordari A
    Asian Pac J Cancer Prev; 2014; 15(20):8693-8. PubMed ID: 25374192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
    Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
    J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
    Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of β-cyclodextrin-helenalin complexes on H-TERT gene expression in the T47D breast cancer cell line - results of real time quantitative PCR.
    Ghasemali S; Nejati-Koshki K; Tafsiri E; Rahmati-Yamchi M; Akbarzadeh A; Alizadeh E; Abbasi M; Barkhordari A; Tozihi M; Kordi S; Zarghami N
    Asian Pac J Cancer Prev; 2013; 14(11):6949-53. PubMed ID: 24377631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.
    Onyüksel H; Mohanty PS; Rubinstein I
    Int J Pharm; 2009 Jan; 365(1-2):157-61. PubMed ID: 18793708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
    Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
    Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
    Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
    Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
    Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
    J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme.
    Saxena V; Hussain MD
    Colloids Surf B Biointerfaces; 2013 Dec; 112():350-5. PubMed ID: 24012704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells.
    Tsui KH; Feng TH; Hsieh WC; Chang PL; Juang HH
    Acta Pharmacol Sin; 2008 Nov; 29(11):1334-41. PubMed ID: 18954528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.
    Saxena V; Naguib Y; Hussain MD
    Colloids Surf B Biointerfaces; 2012 Jun; 94():274-80. PubMed ID: 22377218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.
    Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S
    Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
    Zajac M; Gomez G; Benitez J; Martínez-Delgado B
    BMC Med Genomics; 2010 Oct; 3():44. PubMed ID: 20920318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 17-AAG on the cell cycle and apoptosis of H446 cells and the associated mechanisms.
    Zhao X; Wang J; Xiao L; Xu Q; Zhao E; Zheng X; Zheng H; Zhao S; Ding S
    Mol Med Rep; 2016 Aug; 14(2):1067-74. PubMed ID: 27279418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.